Approved Research This page provides a searchable list of all research protocols that have been reviewed and approved by the Uganda National Council for Science and Technology(UNCST).
Search By Approval Date:
Clear Filter Total: 6,466
Name Title Nationality Approval Date Expiry Date Field of Science/Classification Trial Type Research Type  
Grace Kagoro
ID: UNCST-2021-R013951
 Improved mechanisms for climate change adaptation for sustainable food production
REFNo: NS705ES

Main Objective
1. To improve climate smart agriculture mechanisms and land management practices to cope with climatic variability.

Specific Objectives
1. To establish climatic related environmental hazards, risks & vulnerabilities in small holder farming of SW Uganda.
2. To determine climate smart agricultural practices for adoption to diversify and increase food production in climatic hazard-prone areas.
3. To optimize laboratory infrastructure for analytical capacities in soil, food profiling and plant micro-propagation at MUST.
4. To develop farmer-led crop production and climate monitoring systems for informed food production.
 Uganda 2024-06-05 17:47:58 2027-06-05 Natural Sciences Non-Clinical Trial Degree Award
Linda Calabrese
ID:
Comparative analysis of FDI in Uganda
REFNo: SS1960ES

This research aims to understand whether investment from China is different from that from other countries in terms of its implications for host low- and middle-income countries (LMICs). I operationalise the research in the context of the spillovers generated by Chinese firms and foreign-non Chinese firms on domestic firms. I focus on spillovers because these are important channels of durable productivity transfers between foreign and domestic firms, but one that has mainly been investigated quantitatively and with little comparative analysis.
 Italy 2024-06-05 17:46:42 2027-06-05 Social Science and Humanities Non-Clinical Trial Degree Award
PAULA NJERU
ID:
Utility of An Epilepsy Self-Management And Resilience Technical (SMART) APP for Adolescents and Young Adults
REFNo: HS3799ES

To identify specific improvements for the APP that will make it more useful for AWE and young adults.,To understand aspects of the APP that AWE and young adults derive the greatest benefit from.,To understand the perspectives of adolescents and young adults with epilepsy about using the SMART APP. ,To characterize the experiences of adolescents and young adults with epilepsy while using the SMART APP, pinpoint the essential elements of the APP that adolescents and young adults with epilepsy find most advantageous, and propose specific enhancements to further improve the APP,
 Kenya 2024-06-05 17:45:41 2027-06-05 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Richard Rwabuhinga
ID:
Influence of Competency and performance on Employability in Uganda; A case study of Mountains of the Moon and United Pentecostal Universities
REFNo: HS3058ES

4. The establish the impact of competencies on interpersonal skills of graduates from Mountains of the Moon and United Pentecostal Universities in Mid-western Uganda,3. To find out the influence of competence on problem solving skills of education graduates from Mountains of the Moon and United Pentecostal Universities in Mid-western Uganda.,2. To establish the influence of competence on communication skills among education graduates from Mountains of the Moon and United Pentecostal Universities in Mid-western Uganda.,1. To establish the influence of competence on academic skills among education graduates from Mountains of the Moon and United Pentecostal Universities in Mid-western Uganda.,
 Uganda 2024-06-05 17:44:09 2027-06-05 Medical and Health Sciences Non-Clinical Trial Degree Award
Cissy  Kityo
ID: UNCST-2021-R013663
 A Phase 2a/2b Study Evaluating Safety, Immunogenicity, and Therapeutic Efficacy of ID93 + GLA-SE Vaccination in Participants with Rifampicin-Susceptible Pulmonary TB
REFNo: HS3834ES

1.2 Secondary Objectives 1.2.1 Phase 2a and 2b: To evaluate the proportion of participants with a quantifiable RS ratio after therapeutic vaccination with ID93 + GLA-SE compared to placebo. 1.2.2 Phase 2a: To evaluate the kinetics of cellular immunogenicity of ID93 + GLA-SE through 12 months post second dose of study product. 1.2.3 Phase 2a: To evaluate the kinetics of humoral immunogenicity of ID93 + GLA-SE through 12 months post second dose of study product. 1.2.4 Phase 2a: To evaluate innate immune changes in response to ID93 + GLA-SE through 2 weeks post second dose of study product. 1.2.5 Phase 2b: To compare therapeutic vaccination with ID93 + GLA-SE, to placebo, with respect to the proportion of participants with TB-related unfavorable outcomes at 540 days after study entry, which is approximately 18 months after start of TB treatment, in subgroups defined by: Hard-to-treat phenotype and not hard-to-treat phenotype, where hard-to-treat phenotype is defined as smear Grade ?3 and cavitary disease on chest radiograph at TB diagnosis.1.3 Exploratory Objectives 1.3.1 Phase 2a: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to: • The safety and immunogenicity of ID93 + GLA-SE in participants living with and without HIV. • The quantitative RS ratio at time points relative to vaccination and TB treatment as indicated in the Schedule of Evaluations (SOE). • The magnitude and quality of immune responses with respect to the composition of the intestinal microbiota. 1.3.2 Phase 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to the proportion of participants with TB-related unfavorable outcomes at 540 days after study entry, which is approximately 18 months after start of TB treatment, adjusted for • Pharmacokinetics (PK) assessments of first-line TB drugs (exposure) during TB treatment as per the SOE. • Levels of participant adherence to standard of care (SOC) TB treatment measured using self-reporting and urine acetyl-isoniazid (AcINH) from start to end of TB treatment. 1.3.3 Phase 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to the proportion of participants with TB-related unfavorable outcomes at 540 days after study entry, which is approximately 18 months after start of TB treatment, stratified by bacterial burden at start of TB treatment. 1.3.4 Phase 2a and 2b: To develop the composite predictive model of TB drug response by using measures of adherence, drug exposure (PK), immune response, gut microbiota, and participant phenotype. 1.3.5 Phase 2a and 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to proportion of participants with sputum culture conversion at baseline at time of randomization and at Step 2, Days 30, 120, and 150, which are approximately 2, 5, and 6 months after start of TB treatment. 1.3.6 Phase 2a and 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to cumulative relapse from end of TB treatment up to end of study follow-up, that is, Step 2, Days 420, 450, 480, and 510, for Groups 1, 2, 3 (&5), and 4 (&5), respectively. 1.3.7 Phase 2a and 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to lung function and health-related quality of life, as measured by spirometry and the St. George’s Respiratory Questionnaire. 1.3.8 Phase 2a and 2b: To compare the within-person change in lung function tests over time from the first dose of therapeutic vaccination with ID93 + GLA-SE to placebo. 1.3.9 Phase 2a and 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to resolution of transcriptomic biomarkers of TB disease. 1.3.10 Phase 2b: To identify correlates of protection for unfavorable TB outcomes. 1.3.11 Phase 2b: To estimate the effect of the vaccine on the proportion of participants with TB-related unfavorable outcomes among participants living with and without HIV. 1.3.12 Phase 2a and 2b: To conduct analyses related to furthering the understanding of TB, HIV, immunology, vaccines, and clinical trial conduct.,1.1 Primary Objectives 1.1.1 Phase 2a and 2b: To evaluate safety of a two-dose ID93 + GLA-SE vaccine regimen administered 60 days apart on Step 2, Days 0 and 60, with TB treatment administered, at approximately: 1.1.1.1 Months 4 and 6 after start of TB treatment (Group 1) 1.1.1.2 Months 3 and 5 after start of TB treatment (Group 2) 1.1.1.3 Months 2 and 4 after start of TB treatment (Group 3 and Group 5, if this vaccination schedule is adopted for Group 5) 1.1.1.4 Months 1 and 3 after start of TB treatment (Group 4 and Group 5, if this vaccination schedule is adopted for Group 5) 1.1.2 Phase 2a and 2b: To determine if therapeutic vaccination with ID93 + GLA-SE will increase the magnitude of vaccine-specific cellular responses compared to placebo at 2 weeks post second dose of study product. 1.1.3 Phase 2b: To estimate the effect of the vaccine on the proportion of participants with TB-related unfavorable outcomes (treatment failure, TB recurrence, or death due to TB) at Day 540 after study entry, which is approximately 18 months after start of TB treatment (Group 5 combined with either Group 3 or Group 4, depending on which vaccination schedule is selected for Group 5).,
 Uganda 2024-06-05 17:42:17 2027-06-05 Medical and Health Sciences Clinical Trial Non-degree Award
View Sort By:

"A prosperous Science and Technology Led Ugandan Society."

NRIMS